Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1998;76(1):63–71.

A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.

R T Perry 1, C V Plowe 1, B Koumaré 1, F Bougoudogo 1, K L Kotloff 1, G A Losonsky 1, S S Wasserman 1, M M Levine 1
PMCID: PMC2305629  PMID: 9615498

Abstract

Despite considerable experience with single-dose, live, oral cholera vaccine CVD 103-HgR in Asia, Europe, and the Americas, the vaccine had not been evaluated in sub-Saharan Africa or on individuals infected with human immunodeficiency virus (HIV). We therefore conducted a randomized, placebo-controlled, double-blind, cross-over clinical trial in 38 HIV-seropositive (without clinical acquired immunodeficiency syndrome (AIDS)) and 387 HIV-seronegative adults in Mali to assess its safety and immunogenicity. Adverse reactions (fever, diarrhoea and vomiting) were observed with similar frequency among vaccine and placebo recipients. The vaccine strain was not isolated from the coprocultures of any subject. The baseline geometric mean titre (GMT) of serum vibriocidal antibody was significantly lower in HIV-seropositives (1:23) than in HIV-seronegatives (1:65) (P = 0.002). Significant rises in vibriocidal antibody were observed in 71% of HIV-seronegatives and 58% of HIV-seropositives, and in 40% of HIV-seropositives with CD4+ counts below 500 per microliter. Following immunization, the peak vibriocidal GMT in HIV-seronegatives was 1:584 versus 1:124 in HIV-seropositives (P = 0.0006); in HIV-seropositives with CD4+ counts < 500 per microliter, the peak vibriocidal GMT was 1:40 (P = 0.03 versus other HIV-seropositives). CVD 103-HgR was safe in HIV-infected Malian adults, although serological responses were significantly attenuated among HIV-seropositives (particularly in those with CD4+ counts < 500 per microliter) relative to HIV-seronegatives. These results encourage further evaluations of this single-dose, oral cholera vaccine in high-risk populations such as refugees in sub-Saharan Africa.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benenson A. S., Saad A., Mosley W. H. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ. 1968;38(2):277–285. [PMC free article] [PubMed] [Google Scholar]
  2. Birx D. L., Rhoads J. L., Wright J. C., Burke D. S., Redfield R. R. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr. 1991;4(2):188–196. [PubMed] [Google Scholar]
  3. Bourée P., Lamour P., Bisaro F., Didier E. Etude d'une population d'origine tropicale, VIH positive, dans un centre de réfugiés en France. Bull Soc Pathol Exot. 1995;88(1):24–28. [PubMed] [Google Scholar]
  4. Carson P. J., Schut R. L., Simpson M. L., O'Brien J., Janoff E. N. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis. 1995 Aug;172(2):340–345. doi: 10.1093/infdis/172.2.340. [DOI] [PubMed] [Google Scholar]
  5. Clemens J. D., Sack D. A., Harris J. R., Chakraborty J., Khan M. R., Stanton B. F., Kay B. A., Khan M. U., Yunus M., Atkinson W. Field trial of oral cholera vaccines in Bangladesh. Lancet. 1986 Jul 19;2(8499):124–127. doi: 10.1016/s0140-6736(86)91944-6. [DOI] [PubMed] [Google Scholar]
  6. Clemens J. D., Sack D. A., Harris J. R., Van Loon F., Chakraborty J., Ahmed F., Rao M. R., Khan M. R., Yunus M., Huda N. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990 Feb 3;335(8684):270–273. doi: 10.1016/0140-6736(90)90080-o. [DOI] [PubMed] [Google Scholar]
  7. Clemens J. D., van Loon F., Sack D. A., Chakraborty J., Rao M. R., Ahmed F., Harris J. R., Khan M. R., Yunus M., Huda S. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis. 1991 Jun;163(6):1235–1242. doi: 10.1093/infdis/163.6.1235. [DOI] [PubMed] [Google Scholar]
  8. Clements M. L., Levine M. M., Young C. R., Black R. E., Lim Y. L., Robins-Browne R. M., Craig J. P. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145(4):465–473. doi: 10.1093/infdis/145.4.465. [DOI] [PubMed] [Google Scholar]
  9. Collier A. C., Corey L., Murphy V. L., Handsfield H. H. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988 Jul 15;109(2):101–105. doi: 10.7326/0003-4819-109-2-101. [DOI] [PubMed] [Google Scholar]
  10. Cossa H. A., Gloyd S., Vaz R. G., Folgosa E., Simbine E., Diniz M., Kreiss J. K. Syphilis and HIV infection among displaced pregnant women in rural Mozambique. Int J STD AIDS. 1994 Mar-Apr;5(2):117–123. doi: 10.1177/095646249400500208. [DOI] [PubMed] [Google Scholar]
  11. Eko F. O., Udo S. M., Antia-Obong O. E. Epidemiology and spectrum of vibrio diarrheas in the lower cross river basin of Nigeria. Cent Eur J Public Health. 1994 Jun;2(1):37–41. [PubMed] [Google Scholar]
  12. Glass R. I., Claeson M., Blake P. A., Waldman R. J., Pierce N. F. Cholera in Africa: lessons on transmission and control for Latin America. Lancet. 1991 Sep 28;338(8770):791–795. doi: 10.1016/0140-6736(91)90673-d. [DOI] [PubMed] [Google Scholar]
  13. Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
  14. Glesby M. J., Hoover D. R., Farzadegan H., Margolick J. B., Saah A. J. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis. 1996 Dec;174(6):1332–1336. doi: 10.1093/infdis/174.6.1332. [DOI] [PubMed] [Google Scholar]
  15. Gotuzzo E., Butron B., Seas C., Penny M., Ruiz R., Losonsky G., Lanata C. F., Wasserman S. S., Salazar E., Kaper J. B. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun. 1993 Sep;61(9):3994–3997. doi: 10.1128/iai.61.9.3994-3997.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hatch D. L., Waldman R. J., Lungu G. W., Piri C. Epidemic cholera during refugee resettlement in Malawi. Int J Epidemiol. 1994 Dec;23(6):1292–1299. doi: 10.1093/ije/23.6.1292. [DOI] [PubMed] [Google Scholar]
  17. Huang K. L., Ruben F. L., Rinaldo C. R., Jr, Kingsley L., Lyter D. W., Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA. 1987 Apr 17;257(15):2047–2050. [PubMed] [Google Scholar]
  18. Janoff E. N., Douglas J. M., Jr, Gabriel M., Blaser M. J., Davidson A. J., Cohn D. L., Judson F. N. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. J Infect Dis. 1988 Nov;158(5):983–990. doi: 10.1093/infdis/158.5.983. [DOI] [PubMed] [Google Scholar]
  19. Kotloff K. L., Wasserman S. S., O'Donnell S., Losonsky G. A., Cryz S. J., Levine M. M. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun. 1992 Oct;60(10):4430–4432. doi: 10.1128/iai.60.10.4430-4432.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kroon F. P., van Dissel J. T., de Jong J. C., van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994 Apr;8(4):469–476. doi: 10.1097/00002030-199404000-00008. [DOI] [PubMed] [Google Scholar]
  21. Lagos R., Avendaño A., Prado V., Horwitz I., Wasserman S., Losonsky G., Cryz S., Jr, Kaper J. B., Levine M. M. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun. 1995 Feb;63(2):707–709. doi: 10.1128/iai.63.2.707-709.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  23. Levine M. M., Kaper J. B., Herrington D., Losonsky G., Morris J. G., Clements M. L., Black R. E., Tall B., Hall R. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun. 1988 Jan;56(1):161–167. doi: 10.1128/iai.56.1.161-167.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Levine M. M., Kaper J. B. Live oral vaccines against cholera: an update. Vaccine. 1993;11(2):207–212. doi: 10.1016/0264-410x(93)90019-t. [DOI] [PubMed] [Google Scholar]
  25. Levine M. M., Young C. R., Black R. E., Takeda Y., Finkelstein R. A. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol. 1985 Feb;21(2):174–179. doi: 10.1128/jcm.21.2.174-179.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lewis D. J., Gilks C. F., Ojoo S., Castello-Branco L. R., Dougan G., Evans M. R., McDermott S., Griffin G. E. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS. 1994 Jun;8(6):779–785. doi: 10.1097/00002030-199406000-00009. [DOI] [PubMed] [Google Scholar]
  27. Mahalanabis D., Choudhuri A. B., Bagchi N. G., Bhattacharya A. K., Simpson T. W. Oral fluid therapy of cholera among Bangladesh refugees. Johns Hopkins Med J. 1973 Apr;132(4):197–205. [PubMed] [Google Scholar]
  28. Mosley W. H., Ahmad S., Benenson A. S., Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ. 1968;38(5):777–785. [PMC free article] [PubMed] [Google Scholar]
  29. O'Brien W. A., Grovit-Ferbas K., Namazi A., Ovcak-Derzic S., Wang H. J., Park J., Yeramian C., Mao S. H., Zack J. A. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995 Aug 1;86(3):1082–1089. [PubMed] [Google Scholar]
  30. Rey J. L., Milleliri J. M., Soares J. L., Boutin J. P., Desfontaine M., Merouze F., Van de Perre P. HIV seropositivity and cholera in refugee children from Rwanda. AIDS. 1995 Oct;9(10):1203–1204. doi: 10.1097/00002030-199510000-00019. [DOI] [PubMed] [Google Scholar]
  31. Sack D. A. Cholera control. Lancet. 1994 Aug 27;344(8922):616–617. doi: 10.1016/s0140-6736(94)92003-6. [DOI] [PubMed] [Google Scholar]
  32. Sanchez J. L., Vasquez B., Begue R. E., Meza R., Castellares G., Cabezas C., Watts D. M., Svennerholm A. M., Sadoff J. C., Taylor D. N. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet. 1994 Nov 5;344(8932):1273–1276. doi: 10.1016/s0140-6736(94)90755-2. [DOI] [PubMed] [Google Scholar]
  33. Siddique A. K. Failure of treatment centres to prevent cholera deaths in Goma. Lancet. 1995 Aug 5;346(8971):379–379. doi: 10.1016/s0140-6736(95)92259-8. [DOI] [PubMed] [Google Scholar]
  34. Simanjuntak C. H., O'Hanley P., Punjabi N. H., Noriega F., Pazzaglia G., Dykstra P., Kay B., Suharyono, Budiarso A., Rifai A. R. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis. 1993 Nov;168(5):1169–1176. doi: 10.1093/infdis/168.5.1169. [DOI] [PubMed] [Google Scholar]
  35. St Louis M. E., Porter J. D., Helal A., Drame K., Hargrett-Bean N., Wells J. G., Tauxe R. V. Epidemic cholera in West Africa: the role of food handling and high-risk foods. Am J Epidemiol. 1990 Apr;131(4):719–728. doi: 10.1093/oxfordjournals.aje.a115556. [DOI] [PubMed] [Google Scholar]
  36. Stanley S. K., Ostrowski M. A., Justement J. S., Gantt K., Hedayati S., Mannix M., Roche K., Schwartzentruber D. J., Fox C. H., Fauci A. S. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996 May 9;334(19):1222–1230. doi: 10.1056/NEJM199605093341903. [DOI] [PubMed] [Google Scholar]
  37. Staprans S. I., Hamilton B. L., Follansbee S. E., Elbeik T., Barbosa P., Grant R. M., Feinberg M. B. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995 Dec 1;182(6):1727–1737. doi: 10.1084/jem.182.6.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Su-Arehawaratana P., Singharaj P., Taylor D. N., Hoge C., Trofa A., Kuvanont K., Migasena S., Pitisuttitham P., Lim Y. L., Losonsky G. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992 Jun;165(6):1042–1048. doi: 10.1093/infdis/165.6.1042. [DOI] [PubMed] [Google Scholar]
  39. Suharyono, Simanjuntak C., Witham N., Punjabi N., Heppner D. G., Losonsky G., Totosudirjo H., Rifai A. R., Clemens J., Lim Y. L. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992 Sep 19;340(8821):689–694. doi: 10.1016/0140-6736(92)92231-4. [DOI] [PubMed] [Google Scholar]
  40. Tacket C. O., Losonsky G., Nataro J. P., Cryz S. J., Edelman R., Kaper J. B., Levine M. M. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1992 Oct;166(4):837–841. doi: 10.1093/infdis/166.4.837. [DOI] [PubMed] [Google Scholar]
  41. Tauxe R. V., Holmberg S. D., Dodin A., Wells J. V., Blake P. A. Epidemic cholera in Mali: high mortality and multiple routes of transmission in a famine area. Epidemiol Infect. 1988 Apr;100(2):279–289. doi: 10.1017/s0950268800067418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Van Rensburg E. J., Lemmer H. R., Joubert J. J. Prevalence of viral infections in Mozambican refugees in Swaziland. East Afr Med J. 1995 Sep;72(9):588–590. [PubMed] [Google Scholar]
  43. Wasserman S. S., Losonsky G. A., Noriega F., Tacket C. O., Castañeda E., Levine M. M. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine. 1994 Aug;12(11):1000–1003. doi: 10.1016/0264-410x(94)90335-2. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES